Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Long‐term safety of combination treatment with methotrexate and tumor necrosis factor (TNF)‐α antagonists versus TNF‐α antagonists alone in psoriatic patients

“…Similar to our findings, the most common adverse events under combination treatment in previous studies were liver enzyme elevations and largely attributed to MTX 12,14,22 . Indeed, myelosuppression and liver enzyme abnormalities are well‐known adverse events in psoriatic patients under treatment with MTX 23 .…”

“…Similar to our findings, the most common adverse events under combination treatment in previous studies were liver enzyme elevations and largely attributed to MTX. 12,14,22 Indeed, myelosuppression and liver enzyme abnormalities are well-known adverse events in psoriatic patients under treatment with MTX. 23 In the largest study to date, a randomized controlled trial by Gottlieb et al 14 with 239 patients over 24 weeks, the most common laboratory abnormality considered an adverse event was a GPT increase with an absolute risk of 2.5% versus 1.3% in the group with and without MTX co-treatment, respectively.…”

“…Based on a systematic review from 2015 11 supplemented by a PubMed search for relevant articles in subsequent years (see Methods section), only four studies reported comparative safety data for the combination of etanercept and MTX, [12][13][14][15] and only one study reported comparative safety data for the combination of adalimumab and MTX. 16 All of the studies were limited to a follow up of 24 weeks and only one study reported "real-world" observational data.…”

Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: A meta‐analysis of randomized controlled trials

“…There were 200 studies identified for full-text review. Of those, 15 studies [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] with a total of 4221 patients met the inclusion criteria and were involved in our study (Figure 1). Of the 15 included studies, 10 studies used TNF inhibitors (4 for etanercept, 3 for adalimumab, and each of the rest 3 for infliximab, golimumab, and Yisaipu, respectively), while four studies used IL-17A inhibitors (3 for ixekizumab and one for secukinumab).…”

Comparative Pharmacokinetics, Safety, and Immunogenicity Study of the Prefilled Syringe and Lyophilized Formulation of a Recombinant Human Tumor Necrosis Factor‐α Receptor II:lgG Fc Fusion Protein in Healthy Chinese Male Subjects

“…Recombinant human TNF‐α receptor II:lgG Fc fusion protein (rhTNFR:Fc) is the TNF‐α inhibitor that blocks the action of TNF‐α through targeting and inactivating TNF‐α, and then inhibits inflammation 6 . It effectively alleviates disease activity in patients with RA who inadequately respond to other therapies 7 .…”